OVERVIEW

Molecular Tumor Board Series 2020: Part III is organized by Cancer Treatment Centers of America® (CTCA).

Time to Complete: 1 hour

Released: September 28, 2020
Expires: September 28, 2021

Accreditation:
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Morehouse School of Medicine and Cancer Treatment Centers of America. The Morehouse School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement
The Morehouse School of Medicine designated this enduring activity for a maximum of up to 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent to their participation in the activity.

Description:
A multidisciplinary team discusses treatment options for cancer patients in a tumor board format based on data collected from patients, such as, genetic/genomic testing, pathology and radiological imaging. Cases discussed include: gallbladder carcinoma, triple negative breast cancer, endometrial cancer and adenocarcinoma of unknown primary.

Educational Objectives
Upon completion of this activity, participants will be able to:
• Describe the necessary components of an effective molecular tumor board
• Explain how to integrate genomic profiling into oncology treatment plans